MedPath

Effect of Sacubitril-Valsartan versus angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blocker (ARB) on left ventricular ejection fraction in patient with heart failure

Phase 3
Recruiting
Conditions
Heart failure.
Heart failure
Registration Number
IRCT20120215009014N503
Lead Sponsor
Hamedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
225
Inclusion Criteria

Age 18 to 80 years
Heart failure

Exclusion Criteria

Severe coronary disease
Valvular heart disease
Pulmonary thromboembolism
Congenital heart disease

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Average blood pressure. Timepoint: Every 2 weeks for 6 months after the intervention. Method of measurement: Using a sphygmomanometer.;Mean serum creatinine. Timepoint: Every 2 weeks for 6 months after the intervention. Method of measurement: By taking blood samples.;The average quality of life score. Timepoint: Every 2 weeks for 6 months after the intervention. Method of measurement: Using the New York Heart Association (NYHA) questionnaire.;Left heart ejection fraction. Timepoint: Every 2 weeks for 6 months after intervention. Method of measurement: With echocardiography.;The frequency and duration of hospitalization. Timepoint: Within 6 months after the intervention. Method of measurement: By examining the medical record.;The occurrence of death. Timepoint: Within 6 months after the intervention. Method of measurement: By examining the medical record.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath